State Street Corp Bei Gene, Ltd. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Bei Gene, Ltd. stock. As of the latest transaction made, State Street Corp holds 2,226 shares of BGNE stock, worth $398,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,226

Previous 2,300 3.22%

Holding current value

$398,587

Previous $328,000 52.13%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$143.93 - $224.51 $10,650 - $16,613	-74 Reduced 3.22%	2,226 $499,000
Q2 2024 Aug 14, 2024	SELL	$129.52 - $174.32 $12,952 - $17,432	-100 Reduced 4.17%	2,300 $328,000
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $14,180 - $18,147	100 Added 4.35%	2,400 $375,000
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $32,210 - $40,920	-203 Reduced 8.11%	2,300 $414,000
Q3 2023 Nov 14, 2023	SELL	$179.87 - $225.13 $1.24 Million - $1.55 Million	-6,900 Reduced 73.38%	2,503 $450,000
Q2 2023 Aug 14, 2023	SELL	$178.3 - $266.78 $45.8 Million - $68.5 Million	-256,808 Reduced 96.47%	9,403 $1.68 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $21.5 Million - $27.4 Million	99,974 Added 60.14%	266,211 $57.4 Million
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $72.2 Million - $132 Million	-575,410 Reduced 77.59%	166,237 $36.6 Million
Q3 2022 Nov 15, 2022	SELL	$131.8 - $202.24 $3.3 Million - $5.06 Million	-25,043 Reduced 3.27%	741,647 $100 Million
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $8.34 Million - $14.9 Million	-68,856 Reduced 8.24%	766,690 $124 Million
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $10.8 Million - $19.9 Million	-73,809 Reduced 8.12%	835,546 $158 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $1.06 Million - $1.66 Million	4,273 Added 0.47%	909,355 $246 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $4.64 Million - $7.5 Million	18,594 Added 2.1%	905,082 $329 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $17.6 Million - $22 Million	59,999 Added 7.26%	886,488 $304 Million
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $20.8 Million - $30.5 Million	79,837 Added 10.69%	826,489 $288 Million
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $24.2 Million - $34.6 Million	-109,276 Reduced 12.77%	746,652 $193 Million
Q3 2020 Nov 10, 2020	BUY	$189.18 - $286.44 $14.4 Million - $21.8 Million	76,257 Added 9.78%	855,928 $245 Million
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $8.59 Million - $13.5 Million	-69,309 Reduced 8.16%	779,671 $147 Million
Q1 2020 May 11, 2020	BUY	$121.84 - $173.19 $103 Million - $147 Million	848,980 New	848,980 $105 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Bei Gene, Ltd. Transaction History